Immunome Inc. (IMNM)
$27.70-$1.17 (-4.05%) Today
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 10,500 | $204K |
| Open-market sale | 20 | 692,810 | $15.88M |
| Grant or award | 20 | 1,341,132 | |
| Option exercise | 12 | 523,416 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
44 Form 4 filings on record, the earliest from Nov 25, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Isaac Barchas - Director | Open-market sale | Common Stock | 10,125 | $26.07 | $264K | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 62,291 | $26.23 | $1.63M | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 11,048 | $27.25 | $301K | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 20,840 | $26.06 | $543K | |
| Isaac Barchas - Director | Open-market sale | Common Stock | 15,248 | $26.06 | $397K | |
| Kinney Horn - Officer | Option exercise | Common Stock | 50,366 | $12.92 | $651K | |
| Kinney Horn - Officer | Option exercise | Common Stock | 40,250 | $10.60 | $427K | |
| Kinney Horn - Officer | Open-market sale | Common Stock | 90,616 | $25.09 | $2.27M | |
| Kinney Horn - Officer | Option exercise | Employee Stock Option (right to buy) | 50,366 | $0.00 | - | |
| Kinney Horn - Officer | Option exercise | Employee Stock Option (right to buy) | 40,250 | $0.00 | - | |
| Kinney Horn - Officer | Grant or award | Common Stock | 31,250 | $0.00 | - | |
| Kinney Horn - Officer | Grant or award | Employee Stock Option (right to buy) | 62,500 | $0.00 | - | |
| Philip Tsai - Officer | Grant or award | Common Stock | 38,250 | $0.00 | - | |
| Philip Tsai - Officer | Grant or award | Employee Stock Option (right to buy) | 76,500 | $0.00 | - | |
 Sandra G. Stoneman - Officer | Grant or award | Common Stock | 38,250 | $0.00 | - | |
| Sandra G. Stoneman - Officer | Grant or award | Employee Stock Option (right to buy) | 76,500 | $0.00 | - | |
 Jack Higgins - Officer | Grant or award | Common Stock | 38,250 | $0.00 | - | |
| Jack Higgins - Officer | Grant or award | Employee Stock Option (right to buy) | 76,500 | $0.00 | - | |
 Max Rosett - Officer | Grant or award | Common Stock | 47,250 | $0.00 | - | |
| Max Rosett - Officer | Grant or award | Employee Stock Option (right to buy) | 94,500 | $0.00 | - | |
 Robert Lechleider - Officer | Grant or award | Common Stock | 54,000 | $0.00 | - | |
| Robert Lechleider - Officer | Grant or award | Employee Stock Option (right to buy) | 108,000 | $0.00 | - | |
 Clay B. Siegall - Officer | Grant or award | Common Stock | 180,000 | $0.00 | - | |
| Clay B. Siegall - Officer | Grant or award | Employee Stock Option (right to buy) | 360,000 | $0.00 | - | |
| Kinney Horn - Officer | Option exercise | Common Stock | 1,092 | $12.92 | $14K | |
| Kinney Horn - Officer | Open-market sale | Common Stock | 1,092 | $25.00 | $27K | |
| Kinney Horn - Officer | Option exercise | Employee Stock Option (right to buy) | 1,092 | $0.00 | - | |
| Isaac Barchas | Open-market sale | Common Stock | 83,094 | $24.11 | $2.00M | |
| Isaac Barchas | Open-market sale | Common Stock | 16,906 | $24.20 | $409K | |
| Robert Lechleider - Officer | Option exercise | Common Stock | 55,000 | $8.73 | $480K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 22,714 | $21.95 | $499K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 16,214 | $22.76 | $369K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 16,072 | $23.44 | $377K | |
| Robert Lechleider - Officer | Option exercise | Employee Stock Option (right to buy) | 55,000 | $0.00 | - | |
| Isaac Barchas | Open-market sale | Common Stock | 101,050 | $21.12 | $2.13M | |
| Isaac Barchas | Open-market sale | Common Stock | 75,665 | $22.35 | $1.69M | |
| Isaac Barchas | Open-market sale | Common Stock | 24,335 | $23.33 | $568K | |
| Robert Lechleider - Officer | Option exercise | Common Stock | 55,000 | $8.73 | $480K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 40,580 | $19.56 | $794K | |
| Robert Lechleider - Officer | Open-market sale | Common Stock | 14,420 | $20.66 | $298K | |
| Robert Lechleider - Officer | Option exercise | Employee Stock Option (right to buy) | 55,000 | $0.00 | - | |
| Max Rosett - Officer | Option exercise | Common Stock | 60,000 | $1.05 | $63K | |
| Max Rosett - Officer | Open-market sale | Common Stock | 60,000 | $18.23 | $1.09M | |
| Max Rosett - Officer | Option exercise | Stock Option (right to buy) | 60,000 | $0.00 | - | |
| Sandra M. Swain | Grant or award | Director Stock Option (right to buy)` | 9,897 | $0.00 | - | |
| Philip Wagenheim | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| Jean Jacques Bienaime | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| James P. Boylan | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| Isaac Barchas | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| Carol Schafer | Grant or award | Director Stock Option (right to buy) | 9,897 | $0.00 | - | |
| Jean Jacques Bienaime | Open-market sale | Common Stock | 500 | $19.44 | $10K | |
| Jean Jacques Bienaime | Open-market sale | Common Stock | 10,000 | $19.41 | $194K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 6,000 | $19.48 | $117K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 3,500 | $19.46 | $68K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 1,000 | $19.27 | $19K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 5,000 | $20.70 | $104K | |
| Jack Higgins - Officer | Open-market sale | Common Stock | 9,438 | $21.64 | $204K | |
| Max Rosett - Officer | Option exercise | Common Stock | 31,848 | $1.05 | $33K | |
| Max Rosett - Officer | Option exercise | Common Stock | 39,713 | $1.35 | $54K | |
| Max Rosett - Officer | Open-market sale | Common Stock | 63,656 | $21.91 | $1.39M | |
| Max Rosett - Officer | Open-market sale | Common Stock | 1,344 | $22.48 | $30K | |
| Max Rosett - Officer | Option exercise | Stock option (right to buy) | 31,848 | $0.00 | - | |
| Max Rosett - Officer | Option exercise | Stock option (right to buy) | 39,713 | $0.00 | - | |
| Jack Higgins - Officer | Gift | Common Stock | 6,291 | $0.00 | - | |
| Clay B. Siegall - Officer | Open-market purchase | Common Stock | 25,450 | $19.67 | $501K | |
| Philip Wagenheim | Open-market sale | Common Stock | 36,800 | $20.47 | $753K | |
| Philip Wagenheim | Open-market sale | Common Stock | 28,200 | $20.65 | $582K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 1,000 | $22.12 | $22K | |
| Jean Jacques Bienaime | Open-market purchase | Common Stock | 1,000 | $21.55 | $22K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Barchas Isaac | Director | 11,048 | $301K | View on EDGAR | |
| ABHMC II, LLC | Shareholder | 108,504 | $2.77M | View on EDGAR | |
| Horn Kinney | Officer | 90,616 | $2.27M | View on EDGAR |
Immunome Inc. (IMNM) had 23 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for IMNM runs to 44 Form 4 filings, the earliest from 2024-11-25. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
3 insider purchases of IMNM were filed in the last 90 days, totaling $204K.
20 insider sales of IMNM were filed in the last 90 days, totaling $15.88M.
This page tracks IMNM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IMNM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
